Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in late 2019 in China and is the causative agent of the coronavirus disease 2019 (COVID-19) pandemic. To mitigate the effects of the virus on public health, the economy and society, a vaccine is urgently needed. Here I review the development of vaccines against SARS-CoV-2. Development was initiated when the genetic sequence of the virus became available in early January 2020, and has moved at an unprecedented speed: a phase I trial started in March 2020 and there are currently more than 180 vaccines at various stages of development. Data from phase I and phase II trials are already available for several vaccine candidates, and many have moved into phase III trials. The data available so far suggest that effective and safe vaccines might become available within months, rather than years.
Keywords
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VirologyCoronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakSars virusMedicineOutbreakInfectious disease (medical specialty)
MeSH Terms
AnimalsCOVID-19COVID-19 VaccinesClinical Trials as TopicCoronavirus InfectionsDrug DevelopmentDrug IndustryHumansImmunityMucosalPandemicsPneumoniaViralViral Vaccines
Affiliated Institutions
Related Publications
Review of Current Vaccine Development Strategies to Prevent Coronavirus Disease 2019 (COVID-19)
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) outbreak that started in Wuhan, China, in 2019 resulted in a pandemic not seen for a century, and there is an ur...
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
The safety and immunogenicity data from this U.S. phase 1 trial of two vaccine candidates in younger and older adults, added to earlier interim safety and immunogenicity data re...
Developing Covid-19 Vaccines at Pandemic Speed
Developing Covid-19 Vaccines at Pandemic Speed An ideal vaccine platform would support development from viral sequencing to clinical trials in less than 16 weeks, demonstrate el...
Estimating the Unreported Number of Novel Coronavirus (2019-nCoV) Cases in China in the First Half of January 2020: A Data-Driven Modelling Analysis of the Early Outbreak
Background: In December 2019, an outbreak of respiratory illness caused by a novel coronavirus (2019-nCoV) emerged in Wuhan, China and has swiftly spread to other parts of China...
Publication Info
- Year
- 2020
- Type
- review
- Volume
- 586
- Issue
- 7830
- Pages
- 516-527
- Citations
- 2193
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
2193
OpenAlex
86
Influential
Cite This
Florian Krammer
(2020).
SARS-CoV-2 vaccines in development.
Nature
, 586
(7830)
, 516-527.
https://doi.org/10.1038/s41586-020-2798-3
Identifiers
- DOI
- 10.1038/s41586-020-2798-3
- PMID
- 32967006